Aprotinin: twenty-five years of claim and counterclaim.
Westaby
Stephen
S
D007611:Aprotinin / Q000494:pharmacology / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000401:mortality / Q000517:prevention & control*; D001804:Blood Transfusion, Autologous / Q000009:adverse effects / Q000379:methods; D017277:Drug Approval; D005500:Follow-Up Studies; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D019106:Postoperative Hemorrhage / Q000401:mortality / Q000517:prevention & control*; D015996:Survival Rate; D019616:Thoracic Surgical Procedures / Q000009:adverse effects / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D006490:Hemostatics; D007611:Aprotinin